Charles S. Ryan - 01 Sep 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QNCX	Employee Stock Option (right to buy)	Award	$0	+545,000		$0.000000	545,000	01 Sep 2023	Common Stock	545,000	$1.30	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	25% of the shares subject to the option will vest one year after the date of the grant of September 1, 2023 and the remaining shares will vest in equal monthly installments over the following three years thereafter.